NONMEM Users Network Archive

Hosted by Cognigen

[NMusers] RE: Generating TAD with ADDL dosing format

From: Tim Bergsma <Tim.Bergsma_at_certara.com>
Date: Tue, 20 Dec 2016 13:32:50 +0000

Hi Camila.

If you have access to R, consider the github package "tad" identified below=
. It supports calculation of TAD as a column in your dataset, explicitly c=
onsidering ADDL. Let me know if you have issues installing or operating. =
The following worked for me.

Regards,

Tim

install.packages('devtools')
library(devtools)
install_github('bergsmat/tad')
library(tad)
?tad
example(tad)

Tim Bergsma, PhD
Associate Director
Certara Strategic Consulting
[cid:image003.png_at_01D1D6CC.304CFF80]
m. 860.930.9931
tim.bergsma_at_certara.com<mailto:tim.bergsma_at_certara.com>


From: owner-nmusers_at_globomaxnm.com [mailto:owner-nmusers_at_globomaxnm.com] On=
 Behalf Of de Almeida, Camila
Sent: Tuesday, December 20, 2016 6:46 AM
To: nmusers_at_globomaxnm.com
Subject: [NMusers] Generating TAD with ADDL dosing format

Hello,

I was wondering if I could get some guidance from this great group. My issu=
e is primarily with some diagnostic analysis, but this is taking me back to=
 an old NONMEM problem.

My aim is to run a VPC on a model I implemented, and if possible change the=
 idv to TAD instead of TIME. The reason for that is the VPC graph based on =
TIME looks dreadful as the data is sparse and from different studies of dif=
ferent lengths.

I'm having issues generating the TAD output column from my NONMEM run. I na=
ively assumed I could easily do that, but looking at the NONMEM archives it=
 seems this gets tricky when your dosing events are written using ADDL. Has=
 anyone ever managed to find a solution for this? And if not, is there an a=
lternative way to run the VCP on TAD, do we really need to get this column =
from NONMEM's output?

Thanks all,

Camila de Almeida, PhD
PKPD Scientist,
Modelling & Simulation, IMED Oncology DMPK
___________________________________________________________________________=
_____
AstraZeneca UK Limited
R&D, Innovative Medicines

P Please consider the environment before printing this e-mail








________________________________
AstraZeneca UK Limited is a company incorporated in England and Wales with =
registered number:03674842 and its registered office at 1 Francis Crick Ave=
nue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.
This e-mail and its attachments are intended for the above named recipient =
only and may contain confidential and privileged information. If they have =
come to you in error, you must not copy or show them to anyone; instead, pl=
ease reply to this e-mail, highlighting the error to the sender and then im=
mediately delete the message. For information about how AstraZeneca UK Limi=
ted and its affiliates may process information, personal data and monitor c=
ommunications, please see our privacy notice at www.astrazeneca.com<https:/=
/www.astrazeneca.com> NOTICE: The information contained in this ele=
ctronic mail message is intended only for the personal and confidential =

ttorney-client communication, may be protected by the work product doc=
trine, and may be subject to a protective order. As such, this message is p=
rivileged and confidential. If the reader of this message is not the i=
ntended recipient or an agent responsible for delivering it to the int=
ended recipient, you are hereby notified that you have received this messag=
e in error and that any review, dissemination, distribution, or copyin=
g of this message is strictly prohibited. If you have received this co=
mmunication in error, please notify us immediately by telephone and e-mail =
and destroy any and all copies of this message in your possession (whe=
ther hard copies or electronically stored copies). Thank you. buSp9xeM=
eKEbrUze




image001.png
(image/png attachment: image001.png)

Received on Tue Dec 20 2016 - 08:32:50 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: nmusers-request@iconplc.com. Once subscribed, you may contribute to the discussion by emailing: nmusers@globomaxnm.com.